vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Millrose Properties, Inc. (MRP). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($196.0M vs $189.5M, roughly 1.0× Millrose Properties, Inc.). Millrose Properties, Inc. runs the higher net margin — 64.5% vs -14.6%, a 79.1% gap on every dollar of revenue.
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Millrose Properties, Inc. is a U.S.-based real estate enterprise primarily focused on the acquisition, ownership, operation, and management of income-generating multi-family residential assets. Its core markets span the U.S. Mid-Atlantic and Southeast regions, and it also offers professional property management services to select third-party property owners.
AXSM vs MRP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $189.5M |
| Net Profit | $-28.6M | $122.2M |
| Gross Margin | — | — |
| Operating Margin | -13.8% | 84.8% |
| Net Margin | -14.6% | 64.5% |
| Revenue YoY | 65.0% | — |
| Net Profit YoY | 61.9% | 285.8% |
| EPS (diluted) | $-0.55 | $0.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $189.5M | ||
| Q3 25 | $171.0M | $179.3M | ||
| Q2 25 | $150.0M | $149.0M | ||
| Q1 25 | $121.5M | $82.7M | ||
| Q4 24 | $118.8M | — | ||
| Q3 24 | $104.8M | — | ||
| Q2 24 | $87.2M | — | ||
| Q1 24 | $75.0M | — |
| Q4 25 | $-28.6M | $122.2M | ||
| Q3 25 | $-47.2M | $105.1M | ||
| Q2 25 | $-48.0M | $112.8M | ||
| Q1 25 | $-59.4M | $39.8M | ||
| Q4 24 | $-74.9M | — | ||
| Q3 24 | $-64.6M | — | ||
| Q2 24 | $-79.3M | — | ||
| Q1 24 | $-68.4M | — |
| Q4 25 | -13.8% | 84.8% | ||
| Q3 25 | -27.0% | 85.3% | ||
| Q2 25 | -24.5% | 85.1% | ||
| Q1 25 | -46.9% | 55.2% | ||
| Q4 24 | -61.1% | — | ||
| Q3 24 | -59.8% | — | ||
| Q2 24 | -89.5% | — | ||
| Q1 24 | -89.7% | — |
| Q4 25 | -14.6% | 64.5% | ||
| Q3 25 | -27.6% | 58.6% | ||
| Q2 25 | -32.0% | 75.7% | ||
| Q1 25 | -48.9% | 48.1% | ||
| Q4 24 | -63.1% | — | ||
| Q3 24 | -61.7% | — | ||
| Q2 24 | -91.0% | — | ||
| Q1 24 | -91.1% | — |
| Q4 25 | $-0.55 | $0.74 | ||
| Q3 25 | $-0.94 | $0.63 | ||
| Q2 25 | $-0.97 | $0.68 | ||
| Q1 25 | $-1.22 | $0.39 | ||
| Q4 24 | $-1.54 | — | ||
| Q3 24 | $-1.34 | — | ||
| Q2 24 | $-1.67 | — | ||
| Q1 24 | $-1.44 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $35.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $5.9B |
| Total Assets | $689.8M | $9.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | $35.0M | ||
| Q3 25 | $325.3M | $242.6M | ||
| Q2 25 | $303.0M | $66.6M | ||
| Q1 25 | $300.9M | $89.5M | ||
| Q4 24 | $315.4M | — | ||
| Q3 24 | $327.3M | — | ||
| Q2 24 | $315.7M | — | ||
| Q1 24 | $331.4M | — |
| Q4 25 | $88.3M | $5.9B | ||
| Q3 25 | $73.7M | $5.9B | ||
| Q2 25 | $73.1M | $5.9B | ||
| Q1 25 | $53.2M | $5.9B | ||
| Q4 24 | $57.0M | — | ||
| Q3 24 | $92.9M | — | ||
| Q2 24 | $102.9M | — | ||
| Q1 24 | $144.0M | — |
| Q4 25 | $689.8M | $9.3B | ||
| Q3 25 | $669.3M | $9.0B | ||
| Q2 25 | $639.8M | $8.0B | ||
| Q1 25 | $596.7M | $7.2B | ||
| Q4 24 | $568.5M | — | ||
| Q3 24 | $561.5M | — | ||
| Q2 24 | $548.2M | — | ||
| Q1 24 | $545.7M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $3.7B |
| Free Cash FlowOCF − Capex | $-18.7M | — |
| FCF MarginFCF / Revenue | -9.6% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | 30.05× |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $3.7B | ||
| Q3 25 | $1.0M | $123.1M | ||
| Q2 25 | $-32.4M | $109.1M | ||
| Q1 25 | $-43.4M | $21.3M | ||
| Q4 24 | $-26.2M | — | ||
| Q3 24 | $-18.6M | — | ||
| Q2 24 | $-30.1M | — | ||
| Q1 24 | $-53.5M | — |
| Q4 25 | $-18.7M | — | ||
| Q3 25 | $988.0K | — | ||
| Q2 25 | $-32.4M | — | ||
| Q1 25 | $-43.7M | — | ||
| Q4 24 | $-26.2M | — | ||
| Q3 24 | $-18.7M | — | ||
| Q2 24 | $-30.2M | — | ||
| Q1 24 | $-53.6M | — |
| Q4 25 | -9.6% | — | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | -21.6% | — | ||
| Q1 25 | -36.0% | — | ||
| Q4 24 | -22.1% | — | ||
| Q3 24 | -17.9% | — | ||
| Q2 24 | -34.6% | — | ||
| Q1 24 | -71.4% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | 30.05× | ||
| Q3 25 | — | 1.17× | ||
| Q2 25 | — | 0.97× | ||
| Q1 25 | — | 0.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
